Iovance Biotherapeutics, Inc. IOVA Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Iovance Biotherapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s free cash flow margin?
- Iovance Biotherapeutics, Inc. (IOVA) reported free cash flow margin of -106.8% in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s free cash flow margin changed year-over-year?
- Iovance Biotherapeutics, Inc.'s free cash flow margin increased by 34.6% year-over-year, from -163.4% to -106.8%.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s free cash flow margin?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s free cash flow margin has grown at a -93.7% compound annual growth rate (CAGR), from -32,305.3% to -127.6%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.